AcelRx pain treatment meets late-stage study goal

Mon Mar 4, 2013 6:25pm EST

Related Topics


Ebola epidemic

Quarantines and isolation units imposed to stop the spread of the worst Ebola outbreak in history.  Slideshow 

(Reuters) - AcelRx Pharmaceuticals Inc said its experimental drug-device combination for post-operative pain met the main goal of a late-stage study on patients who have undergone major open abdominal surgery.

AcelRx shares jumped 10 percent to $5.49 after the bell on Monday.

The top-line results reported from a 178-patient study of AcelRx's sublingual Sufentanil NanoTab PCA system showed that the patient-controlled drug-device combination helped reduce pain significantly compared with a placebo, the company said.

(Reporting by Zeba Siddiqui in Bangalore; Editing by Roshni Menon)

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.